{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:09:45Z","timestamp":1768000185339,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Data on effects of intra-gastric balloon (IGB) on metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce, in part with contradictory results, and mainly obtained in tertiary care patients with diabetes and other comorbidities. We here explore effects of IGB in patients with MASLD referred to a first-line obesity clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective cohort study, patients with at least significant fibrosis (\u2265\u2009F2) and\/or severe steatosis (S3) according to screening transient elastography (FibroScan\u00ae) were offered a second FibroScan\u00ae after 6 months lifestyle modification with or without IGB (based on patient preference). <jats:italic>Results<\/jats:italic>: 50 of 100 consecutively screened patients (generally non-diabetic) qualified for repeated evaluation and 29 (58%) of those had a second FibroScan\u00ae. At baseline, at least significant fibrosis was present in 28% and severe steatosis in 91%. IGB was placed in 19 patients (59%), whereas 10 patients (41%) preferred only lifestyle modification (no differences in baseline characteristics between both groups). After 6 months, liver stiffness decreased markedly in the IGB group (median: from 6.0 to 4.9 kPa, p\u2009=\u20090.005), but not in the lifestyle modification only group (median: from 5.5 to 6.9 kPa, p\u2009=\u20090.477). Steatosis improved in both groups, (controlled attenuation parameter values; IGB, mean\u2009\u00b1\u2009SD: from 328\u2009\u00b1\u200934 to 272\u2009\u00b1\u200962 dB\/m, p\u2009=\u20090.006: lifestyle modification only, mean\u2009\u00b1\u2009SD: from 344\u2009\u00b1\u200933 to 305\u2009\u00b1\u200943 dB\/m: p\u2009=\u20090.006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both steatosis and fibrosis improve markedly in overweight\/obese patients with MASLD after 6 months IGB combined with lifestyle modification. Our results warrant further research into long-term effect of IGB in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11739-023-03417-2","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:01:37Z","timestamp":1694538097000},"page":"2271-2280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-2434","authenticated-orcid":false,"given":"A. M.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"El-Morabit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. T.","family":"Bac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. W.","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. E.","family":"van der Schuit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M. C.","family":"Hirdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de Bruijne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"van Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A. H.","family":"Kaasjager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. W.","family":"de Valk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P.","family":"Vleggaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"3417_CR1","doi-asserted-by":"publisher","unstructured":"Rinella ME, Lazarus J V, Ratziu V, et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature Authors. Hepatology Publish Ahead of Print. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","DOI":"10.1097\/HEP.0000000000000520"},{"key":"3417_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3417_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3417_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Koenig A, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"3417_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jhep.2005.06.008","volume":"43","author":"A Suzuki","year":"2005","unstructured":"Suzuki A, Lindor K, Saver JS et al (2005) Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43:1060\u20131066. https:\/\/doi.org\/10.1016\/j.jhep.2005.06.008","journal-title":"J Hepatol"},{"key":"3417_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","volume":"55","author":"G Musso","year":"2012","unstructured":"Musso G, Cassader M, Rosina F, Gambino R (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia 55:885\u2013904. https:\/\/doi.org\/10.1007\/s00125-011-2446-4","journal-title":"Diabetologia"},{"key":"3417_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367-378.e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"3417_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121\u2013129. https:\/\/doi.org\/10.1002\/hep.23276","journal-title":"Hepatology"},{"key":"3417_CR9","doi-asserted-by":"publisher","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA et al (2021) The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 115:154455. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455","journal-title":"Metabolism"},{"key":"3417_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","volume":"179","author":"DA Koutoukidis","year":"2019","unstructured":"Koutoukidis DA, Astbury NM, Tudor KE et al (2019) Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med 179:1262\u20131271. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2248","journal-title":"JAMA Intern Med"},{"key":"3417_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL) (2016) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121\u20131140. https:\/\/doi.org\/10.1007\/s00125-016-3902-y","journal-title":"Diabetologia"},{"key":"3417_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D et al (2022) American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of. Endocr Pract 28:528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"key":"3417_CR13","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM et al (2014) 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology\/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol 63:2985\u20133023. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.004","journal-title":"J Am Coll Cardiol"},{"key":"3417_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","volume":"17","author":"L Agarwal","year":"2021","unstructured":"Agarwal L, Sahu AK, Baksi A et al (2021) Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. Surg Obes Rel Dis 17:525\u2013537. https:\/\/doi.org\/10.1016\/j.soard.2020.11.004","journal-title":"Surg Obes Rel Dis"},{"key":"3417_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.14309\/ajg.0000000000000239","volume":"114","author":"F Bazerbachi","year":"2019","unstructured":"Bazerbachi F, Vargas EJ, Abu Dayyeh BK (2019) Endoscopic bariatric therapy: a guide to the intragastric balloon. Am J Gastroenterol 114:1421\u20131431. https:\/\/doi.org\/10.14309\/ajg.0000000000000239","journal-title":"Am J Gastroenterol"},{"key":"3417_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1053\/j.gastro.2017.01.035","volume":"152","author":"BK Abu Dayyeh","year":"2017","unstructured":"Abu Dayyeh BK, Edmundowicz S, Thompson CC (2017) Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology 152:716\u2013729. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.035","journal-title":"Gastroenterology"},{"key":"3417_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s11695-020-05084-0","volume":"31","author":"S Chandan","year":"2021","unstructured":"Chandan S, Mohan BP, Khan SR et al (2021) Efficacy and Safety of Intragastric Balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a comprehensive review and meta-analysis. Obes Surg 31:1271\u20131279. https:\/\/doi.org\/10.1007\/s11695-020-05084-0","journal-title":"Obes Surg"},{"key":"3417_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","volume":"19","author":"F Bazerbachi","year":"2021","unstructured":"Bazerbachi F, Vargas EJ, Rizk M et al (2021) Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19:146-154.e4. https:\/\/doi.org\/10.1016\/j.cgh.2020.04.068","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3417_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.gie.2009.06.036","volume":"71","author":"R Forlano","year":"2010","unstructured":"Forlano R, Ippolito AM, Iacobellis A et al (2010) Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc 71:927\u2013933. https:\/\/doi.org\/10.1016\/j.gie.2009.06.036","journal-title":"Gastrointest Endosc"},{"key":"3417_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.gie.2012.05.023","volume":"76","author":"YM Lee","year":"2012","unstructured":"Lee YM, Low HC, Lim LG et al (2012) Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc 76:756\u2013760. https:\/\/doi.org\/10.1016\/j.gie.2012.05.023","journal-title":"Gastrointest Endosc"},{"key":"3417_CR21","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1111\/liv.14917","volume":"41","author":"F Salomone","year":"2021","unstructured":"Salomone F, Currenti W, Magr\u00ec G et al (2021) Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. Liver Int 41:2112\u20132116. https:\/\/doi.org\/10.1111\/liv.14917","journal-title":"Liver Int"},{"key":"3417_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07596-4","author":"R Vijayaraghavan","year":"2022","unstructured":"Vijayaraghavan R, Sarin SK, Bharadwaj A et al (2022) Intragastric balloon in obese compensated nonalcoholic steatohepatitis cirrhosis patients is safe and achieves significant weight reduction at 6 - months. Dig Dis Sci. https:\/\/doi.org\/10.1007\/s10620-022-07596-4","journal-title":"Dig Dis Sci"},{"key":"3417_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jhep.2021.06.013","volume":"75","author":"X Chen","year":"2021","unstructured":"Chen X, Chen S, Pang J et al (2021) Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol 75:987\u2013989","journal-title":"J Hepatol"},{"key":"3417_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","volume":"16","author":"YC Zhang","year":"2022","unstructured":"Zhang YC, Lyu ZY, Ma B et al (2022) A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatol Int 16:835\u2013845. https:\/\/doi.org\/10.1007\/s12072-022-10362-3","journal-title":"Hepatol Int"},{"key":"3417_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209","journal-title":"J Hepatol"},{"key":"3417_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.01.029","author":"Z-Q Xie","year":"2023","unstructured":"Xie Z-Q, Li H-X, Wang B-K et al (2023) Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: results from the NHANES study. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2023.01.029","journal-title":"Eur J Intern Med"},{"key":"3417_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J et al (2021) EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update. J Hepatol 75:659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","journal-title":"J Hepatol"},{"key":"3417_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11695-013-1149-y","volume":"24","author":"RJ Marek","year":"2014","unstructured":"Marek RJ, Ben-Porath YS, Merrell J et al (2014) Predicting one and three month postoperative somatic concerns, psychological distress, and maladaptive eating behaviors in bariatric surgery candidates with the Minnesota multiphasic personality inventory-2 restructured form (MMPI-2-RF). Obes Surg 24:631\u2013639. https:\/\/doi.org\/10.1007\/s11695-013-1149-y","journal-title":"Obes Surg"},{"key":"3417_CR29","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4158\/GL-2019-0406","volume":"25","author":"JI Mechanick","year":"2019","unstructured":"Mechanick JI, Apovian C, Brethauer S et al (2019) Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored By American Association of Clinical Endocrinologists\/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - Executive Summary. Endocr Pract 25:1346\u20131359. https:\/\/doi.org\/10.4158\/GL-2019-0406","journal-title":"Endocr Pract"},{"key":"3417_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.psychres.2012.07.035","volume":"200","author":"I Carlier","year":"2012","unstructured":"Carlier I, Schulte-Van Maaren Y, Wardenaar K et al (2012) Development and validation of the 48-item Symptom Questionnaire (SQ-48) in patients with depressive, anxiety and somatoform disorders. Psychiatry Res 200:904\u2013910. https:\/\/doi.org\/10.1016\/j.psychres.2012.07.035","journal-title":"Psychiatry Res"},{"key":"3417_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1073\/pnas.4.12.370","volume":"4","author":"J Harris","year":"1918","unstructured":"Harris J, Benedict F (1918) A biometric study of human basal metabolism. Proc Natl Acad Sci 4:370\u2013373. https:\/\/doi.org\/10.1073\/pnas.4.12.370","journal-title":"Proc Natl Acad Sci"},{"key":"3417_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"3417_CR33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M et al (2019) Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1717\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042","journal-title":"Gastroenterology"},{"key":"3417_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","volume":"100","author":"M de Vries","year":"2022","unstructured":"de Vries M, El-Morabit F, van Erpecum KJ et al (2022) Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. Eur J Intern Med 100:77\u201382. https:\/\/doi.org\/10.1016\/j.ejim.2022.03.025","journal-title":"Eur J Intern Med"},{"key":"3417_CR35","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002098","author":"JG Stine","year":"2022","unstructured":"Stine JG, DiJoseph K, Pattison Z et al (2022) Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Am J Gastroenterol. https:\/\/doi.org\/10.14309\/ajg.0000000000002098","journal-title":"Am J Gastroenterol"},{"key":"3417_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956\u2013965. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4","journal-title":"Lancet"},{"key":"3417_CR37","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184\u20132196. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"},{"key":"3417_CR38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V et al (2021) A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH. N Engl J Med 385:1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2036205","journal-title":"N Engl J Med"},{"key":"3417_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu14214673","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M et al (2022) Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study. Nutrients 14:1. https:\/\/doi.org\/10.3390\/nu14214673","journal-title":"Nutrients"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03417-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03417-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03417-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:25:36Z","timestamp":1699547136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03417-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3417"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03417-2","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The local Medical Ethical Committee has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All included participants provided written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}